Antibody could be first new mechanism of action for HIV treatment in 10 years

Theratechnologies (TSE:TH) said today that the FDA granted priority review to the biologics license application for ibalizumab as a treatment for multi-drug resistant HIV-1.

If the monoclonal antibody is approved, it will be the first antiretroviral treatment with a new mechanism of action to be introduced in a decade. It would also be the only available therapy that doesn’t necessitate daily dosing.

Get the full story at our sister site, Drug Delivery Business News.

The post Antibody could be first new mechanism of action for HIV treatment in 10 years appeared first on MassDevice.

from MassDevice http://ift.tt/2szsXtD